Isto Biologics has acquired TheraCell as is looks to increase its focus on offering solutions for surgical and clinical care procedures within spine, orthopaedics, and sports medicine.
Don Brown, CEO of Isto Biologics, said: “We are thrilled to add TheraCell’s unmatched technology to our market leading biologics portfolio. TheraCell has excelled in developing advanced bone integrating, anchoring, and bridging technologies for spinal repair for over a decade including their award winning TheraFuze DBF Fiber Anchor and TheraFuze DBF Fiber Bag.”
Bradley Patt, TheraCell’s co-founder and CEO, added: “We are pleased that Isto, a leader in allogeneic spine solutions, has recognised the value and importance of what we have developed and are excited about how their patient-centric, outcomes-focused commercial and clinical teams will rapidly accelerate the surgical adoption of the products and technology that we are so passionate about.”
Nelson Scarborough, TheraCell’s chief scientific officer and co-inventor of the TheraFuze DBF Fiber Bag, commented: “The versatility of our technology platform has allowed us to develop and commercialise a range of procedure-specific fibre graft forms. We are thrilled with the opportunity to expand utilisation of this unique product portfolio through Isto’s presence in the orthopaedic allograft market.”
“We believe TheraCell’s DBF Fiber products are a great fit with Isto’s existing portfolio and we anticipate the merging of our organisations to have a tremendous impact in the market” concluded Andy Carter, TheraCell’s chief technology officer and co-inventor of the TheraFuze DBF Fiber Anchor.
